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Optimal correction of acidosis changes progression of dialysis osteodys-
trophy. To investigate an eventual role of acidosis on hemodialysis
osteodystrophy we prospectively studied 21 patients who were dialyzed
with different amounts of bicarbonate in the dialysate for 18 months.
According to the level of bone formation rate (BFR) on a prestudy bone
biopsy, patients were split in two subgroups. Inside these two sub-
groups patients were randomly allocated to two therapeutics groups: 10
patients (group A) were dialyzed with the conventional amount of
bicarbonate (33 2 mmollliter) in the dialysate; the rest of the patients
(group B, N = 11) had 7 to 15 mmollliter sodium bicarbonate added to
the dialysate to obtain 24 mEq predialysis bicarbonate plasma levels.
An effective correction of acidosis was shown in group B by a higher
predialysis plasma bicarbonate level (15.6 I group A vs. 24.0 0.6
mEq/liter group B, P C 0.005), which was reached three months after
start of the study. Compared to the prestudy bone biopsy, osteoid and
osteoblastic surfaces increased in group A but not in group B on the
bone biopsies performed at the end of the study. Parathormone plasma
level (iPTH), measured with an antiserum which cross reacts with the
44-68 region of VFH molecule, increased during the study in group A
but not in group B. This finding suggested progression of secondary
hyperparathyroidism (HPT) only in group A patients. Osteocalcin
plasma values increased in both groups during the 18 months of the
study. Consequently the two subgroups of patients formed on the basis
of BFR level were evaluated separately. The subgroup of patients with
normal-high BFR on the prestudy bone biopsy had a high bone
resorption and elevated iPTH and osteocalcin plasma levels at start of
the study. In this subgroup of patients, the osteocalcin plasma level
increased more in group A than in group B during the study. The
subgroup of patients with normal-low BFR had lower osteocalcin
levels, and seven often patients had aplastic bone disease at start of the
study. In this subgroup, osteocalcin plasma values were unchanged
during the study in group A but increased in group B. There was no
significant modification of plasma or bone aluminium in any group
during the time of the study. Therefore, an optimal correction of
acidosis could decrease progression of HPT in patients with high bone
turnover, and stimulate bone turnover in patients with low bone
formation.
Renal osteodystrophy is the result of a constellation of
metabolic disorders related to renal failure [1]. Phosphate
retention and abnormal vitamin D metabolism are believed to
trigger hypocalcemia and subsequent parathyroid hyperplasia
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[2, 31. More recently it has been shown also that iatrogenic bone
aluminium overload is an important determinant of renal oste-
odystrophy, often associated with osteomalacia and aplastic
bone disease [41. However, other metabolic abnormalities oc-
cur during renal osteodystrophy and their respective role is far
from clear. Among them, acidosis has been suspected to have
some role in renal failure bone lesions. Indeed, during chronic
acidosis bone carbonates buffers the metabolic acid load: bone
carbonate is decreased in uremic [5] patients. In patients with
end-stage renal failure acidosis has been shown to be frequently
associated with osteomalacia [6]. However, early studies failed
to show any improvement of osteomalacia in acidotic uremic
patients treated with bicarbonate [7, 8]. Acidosis is not com-
pletely corrected by dialysis therapy [91; its eventual role in
dialysis osteodystrophy has not yet been investigated. We
therefore prospectively compared two groups of patients dia-
lyzed for 18 months with different amounts of bicarbonate in the
dialysate. Our results suggest that a better correction of dialysis
acidosis can prevent progression of secondary hyperparathy-
roidism in hemodialyzed patients.
Methods
Patient selection
Twenty-one dialyzed patients completed the study. Patient
selection for the study was made on the following criteria: 1)
patients had to give their informed consent to participate to this
study which included 2 bone biopsies; 2) patients with severe
radiological osteitis fibrosa, plasma calcium above 11 mg/dl,
parathyroidectomy, diabetes mellitus and treatment by cortico-
steroid were excluded from the study.
Patient subgroups
One to three months before the start of the study the selected
patients had a bone biopsy. According to the level of bone
formation rate on this bone biopsy, patients were classified in
either low-normal (N = 10) or high-normal (N = 11) bone
formation rate subgroups. There was no significant difference in
age, sex, initial nephropathy, duration of dialysis and pre-study
treatment between two subgroups (data not shown). This strat-
ification according to prestudy bone morphometry was done to
have an equivalent spectrum of bone disease in the two different
treatment groups. Half of the patients in either the high-normal
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or the low-normal bone formation rate subgroups were then
randomly allocated to the control group (N = 10), and the rest
of them (N = 11) to the acidosis corrected group.
Dialysis therapy
The study lasted 18 months. The patients of the control group
had no change in their dialysis treatment compared to prestudy
time. They were dialyzed for four hours three times weekly,
with water treated by reverse osmosis and containing: K 2 to 3
mmol/liter, calcium 1.75 mmol/liter, magnesium 0.75 mmol/
liter, sodium 143 2 mmol/liter, and 33 2 mmol/liter
bicarbonate. In the acidosis corrected group the dialysate
composition was the same except that a sodium bicarbonate
concentrate solution was added and sodium chloride reduced so
that sodium in the dialysate was 143 2 mmol/liter. During the
first four to six weeks of the study, a fixed amount of 7 mEq/liter
of bicarbonate was added to the dialysate. During this period,
predialysis plasma bicarbonate increased from one to the fol-
lowing dialysis in each patient. A steady predialysis plasma
bicarbonate level was achieved in each patient. The amount of
sodium bicarbonate added was then adjusted in each patient to
obtain a predialysis bicarbonate value of approximately 24
mEq/liter. The amount of sodium bicarbonate needed in dialy-
sate varied from 7 to 15 mEq/liter depending on the patients.
Associated treatments
Six patients in the control group and five patients in the
acidosis corrected group had antihypertensive drugs. No other
treatment was given to the patients except for phosphate
binder, calcium carbonate and vitamin D. These three treat-
ments were prescribed according to the biological data: phos-
phate binder (1 to 5 g aluminium gel) when plasma phosphate
was above 6 mg/dl, calcium carbonate up to 4 g a day to obtain
plasma calcium level above 9.0 mg/dl, and la vitamin D (up to
0.75 pg/day) was prescribed when a 9.0 mgldl plasma calcium
level could not be achieved with 4 g of calcium carbonate alone.
Biochemical measurements
Predialysis pH, pre- and postdialysis creatinine, sodium,
potassium, chloride, calcium, phosphate were measured every
two weeks by automated method (SMAC). Plasma alkaline
phosphatase, aluminum, immunoactive parathormone (iPTH),
and osteocalcin were measured every three months. Plasma
iPTH was measured by radioimmunoassay using 53-84 and
44-68 antibodies raised in sheep. The characteristics of the
assays are as follows: A C-terminal PTH antiserum was raised
in sheep immunized with synthetis hPTH (53-84). The tracer
used was S2-Tyr-hPTH 53-84 radioiodinated using the chloram-
me T procedure and purified by HPLC. The bioiodinated
fraction of the tracer was used after dilution in order to obtain
20 pg/mI of tracer per tube. Synthetic hPTH (5 3-84) was used as
the standard. Standards or samples were incubated with anti-
PTH antibody used at 1/100,000 dilution. After 24 hours at 4°C,
radioiodinated PTH was added. After an additional day at 4°C,
antibody-['251]PTH complexes were precipitated and quanti-
fied. The limit of detection of the assay was 10 pg/mI and the
normal range was 20 to 45 pglml.
PTH was also determined with a mid region assay. The
antiserum was raised in sheep using synthetic hPTH-44-68.
Radioiodinated synthetic 43Tyr-hPTH (44-68) was used as a
tracer, and hPTH (44-68) was used as the standard. The
procedure used was similar as for the C-terminal PTH assay
except that the antiserum was diluted at 1: 25,000. The limit of
detection was 50 pg/ml and the normal range was 80 to 220
pg/mi. At the end of the study 1-84 PTH was also measured
using an N-terminal antibody recognizing the entire molecule
(Nicois Institute). The normal range was 10 to 65 g/ml.
Osteocalcin was measured by radioimmunoassay using an
antibody raised against bovine osteocaicin (ORIS CEA,
France). The normal range was 4 to 9 nglml. Serum aluminum
was measured every month by atomic absorption spectropho-
tometry in a graphite furnace.
Bone histomorphometry
Bone biopsies were performed one to three months before the
start of the study and repeated in every patient 18 months after
the start of the study. Bone histomorphometry was assessed
after double tetracycline labeling according to the following
schedule: two days on tetracycline, ten days off, two days on.
Bone biopsy was performed two days after the last tetracycline
dose on the anterior iliac crest. Measurements were performed
in trabecular bone as already described [10]. Bone volume,
osteoid volume, osteoid surface, osteoblast and osteoclast
surfaces (%) were measured on three sections stained by
toluidine blue. Osteoblast surfaces are the trabecular surfaces
covered with plump osteoblasts, surfaces are the trabecular
surfaces in contact with an osteoclast independently of the
existence of a lacuna. Osteoid thickness was measured with an
image analyzer at equidistant points on all the trabecular bone
and was expressed in ,sm. Mineral apposition rate and the
extent of single and double surfaces were assessed on two
unstained, 10 m thick sections. Mineralizing surfaces were
determined from the double-labeled surfaces plus single-labeled
surfaces divided by two. Bone formation rate (BFR, tm3//Lm2
per day) was calculated as mineralization rate multiplied by
total labeled surfaces. Normal values from our laboratory have
been previously published [10]. Normal range for bone forma-
tion rate is 0.08 0.03 p,m3/pm2/day. Therefore the value of
0.08 m3/m2/day was chosen to split patients in two subgroups
one the pre-study bone biopsy. Sections were stained for
aluminum by the aurin tricarboxylic acid method. The percent-
age of trabecular surfaces stained with aluminum, whether or
not they were covered by osteoid, was also measured. Two
bone samples obtained at the end of the study were uninterpret-
able and one patient refused his bone biopsy.
Statistical methods
Comparison between control and acidosis corrected groups
were performed by unpaired Student's t-test for which usual
assumptions (Gaussian repartition, homoscedasticity) were sat-
isfied. When smaller groups (determined by high or low level of
bone formation rate) were formed, we used a non-parametric
two-way analysis of variance on ranks (Friedman's test). Anal-
ysis of the differences between initial and final values inside
each of the two groups of patients was done by Student's paired
t-test and/or analysis of variance. The evolution all along the
period of treatment was analyzed by mean of linear regression;
heterogeneity of slopes was assessed by testing interaction
between time and group of treatment inside a linear model of
variance analysis. Calculus calculations were performed using
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Table 1. Biochemical and bone histomorphometric parameters in the
two subgroups defined on bone histomorphometry basis before start
of the study
Normal-low Normal-high
bone formation bone formation
rate rate Normal
N=l0 N=ll values
Plasma 53-84 PTH 266.5 38.8 545.9 80.6k' 20—45
pg/mi
Plasma 44-68 PTH 1261 395 2937 719 80—220
pg/mi
Plasma osteocalcin 11.2 2.6 26.2 2.6k
ng/m!
Extent of stainable 67.5 10.9 40.9 9.8
aluminum
surfaces on bone
biopsy %
Bone formation rate 0.009 0.005 0.128 0.038" 0.08 0.03
jun3/p.m2/day
Osteoblastic 0.6 0.3 7,1 2,3a 3.6 1.2
surfaces %
Resorption surface 0.5 0.2 2.8 0.5" 0.5 0.2
%
Values are expressed by mean SEM.
Different from patients with normal low bone formation rate: "P <
0.05, ' P C 0.01
the SAS package (ANOVA, fiLM, REG, NPAR and T TEST
procedures). Significant differences correspond to P values less
than 0.05.
Results
Among the 21 patients of the study, eleven had a bone
formation rate superior to the normal value (0,08 rm3/,am2/day)
and ten had a bone formation rate below this normal value.
These two groups of patients, defined according to bone forma-
tion rate levels, had different biochemical and histological
results (Table 1). Before the start of the study, plasma 53-84
iPTH and osteocalcin plasma levels were higher in the normal-
high formation group. Bone formation rate, osteoblastic and
osteoclastic resorption surfaces were also higher and increased
above control values in the normal-high bone formation sub-
group. Among the 10 patients with normal-low bone formation
rate, seven had a value below 0.031 jzm3/jzm2/day, the lowest
value of our control group, and a mean osteoid thickness below
15 jim. They could be classified as aplastic bone disease
patients. None of the patients met the histological criteria for
osteomalacia. The two treatment groups were randomly formed
among these two subgroups (Methods). The clinical spectrum of
the control and acidosis corrected groups were the same: there
were five females and five males in the control group, and six
females and five males in acidosis corrected group. Ages were
49.9 14.1 in controls and 51.2 9.1 in the acidosis corrected
group. Duration of dialysis was 6.2 3.0 years in controls and
6.6 3.3 in the acidosis corrected group. Initial nephropathy
was not different between both groups. Biochemical (ionogram,
calcium phosphate metabolism) and bone histomorphometric
values at start of the study were also the same in the two
treatment groups (Tables 2, 3 and 4).
The addition of bicarbonates in dialy sate induced an effective
increase in predialysis bicarbonate and pH in the eleven pa-
tients of the acidosis corrected group (Table 2). As displayed in
Table 2. lonogram at start
(group A, N = 10) and a
and at the end of the st
cidosis corrected (grou
udy in controls
p B, N = 11)
patients
Start of End of
Group the study the study
Predialysis bicarbonate A 16.80 0.92 16.50 0.88
mEq/iiter B 15.64 1.06 24.00 0.61"
Postdialysis bicarbonate A 20.80 1.07 19.40 0.92
mEq/liter B 21.00 0.88 29.00 0.57"
Predialysis
pH A 7.35 0.02
B 7.35 0.02
7.35 0.02
7.39 0.01"
P°2 A 96.50 4.70
B 93.80 6.18
88.50 4.24
76.70 2.03
pCO2 A 34.70 1.26
B 35.30 2.17
35.60 2.04
37.70 0.89
Creatinine mg/di A 12.09 0.60
B 11.52 0.83
11.73 0.57
10.40 0.60
Protein g/dl A 7.2 0.1
B 7.1 0.1
7.3 0.1
7.1 0.1
Hematocrit % A 29.10 2.08
B 30.40 1.81
31.00 2.65
31.50 1.77
Predialysis potassium A 5.38 0.22 5.56 0.14
mEq/liter B 5.47 0.15 5.15 0.24
Postdialysis potassium A 3.62 0.12 3.50 0.13
mEq/iiter B 3.78 0.13 3.55 0.08
Values are expressed by mean 5EM. If not mentioned, predialysis
samples were analyzed.
"Significantly different (P C 0.05) from the value at start of the study
Table 3. Calcium and phosphate metabolism plasma values in control
(group A, N = 10) and acidosis corrected (group B, N = 11) patients
Start of End of
Group the study the study
Predialysis calcium A 9.3 0.1 9.3 0.1
mg/dl B 9.5 0.1 9.2 0.2
Postdialysis calcium A 11.9 0.3 12.0 0.4
mg/di B 11.2±0.2 11.2±0.3
Predialysis phosphate A 5.1 0.2 5.5 0.3
mg/dl B 5.1 0.3 4.6 0.6
Postdialysis phosphate A 3.6 0.2 2.9 0.2
mg/dl B 3.0 0.2 2.7 0.2
Alkaline phosphatase A 99.5 13.3 132.9 35.3
lU/liter B 74.9 9.0 80.9 14.8
53-84 PTH pg/mi A 429.0 95.9 374.4 82.9
(N = 20—45) B 398.2 62.7 335.7 70.3
44-68 PTH pg/mi A 1904 649 5277 1528
(N = 80—220) B 2354 652 3405 1033
1-84 PTH pg/mi A ND 234 88
(N=l0-65) B ND 126±35
Osteocalcin ng/ml A 19.5 3.9 60.0 24.0
(N = 4—9) B 18.7 3.2 34.8 11.3
Aluminum tg/mi A 33.2 19.4 32.1 18.1
B 34.6 17.5 42.1 17.8
Values are expressed by mean 5EM in controls (A) and acidosis
corrected (B) patients. None of the values are significantly different. If
not mentioned, predialysis samples were analyzed. ND, not deter-
mined.
Figure 1, this effect was significant from three months after the
start of the study and remained steady all along the course of
the study. In both groups there were no changes in plasma
proteins, creatinine, hematocrit and potassium between the
start and the end of the study (Table 2). However, in the
acidosis corrected group, there was a decrease in postdialysis
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Group
Start of
the study N End of study N
Bone volume % A
B
22.88 3.06
23.01 1.95
10
11
20.22 2.53
21.77 2.86
9
9
Osteoid volume % A
B
5.32 0.98
6.03 1.44
10
11
15.06 2.51"
12.49 2.29a
9
9
Osteoid surfaces % A
B
39.03 7.21
41.30 8.59
10
11
60.35 5.57"
57.57 4.97
9
9
Osteoblast surfaces % A
B
3.53 1.14
4.38 2.49
10
11
9.87 2.37k'
5.32 1.33
9
9
Osteoclast surfaces % A
B
1.75 0.53
1.67 0.51
10
11
1.67 0.61
0.98 0.24
9
9
Osteoclasts/mm2 A
B
0.84 0.24
1.06 0.35
10
11
1.33 0.59
0.82 0.22
9
9
Bone formation rate A 0.077 0.025 10 0.135 0.053 9
pm3/p,n2/day B 0.085 0.045 10 0.041 0.020 9
Osteoid thickness pm A
B
9.3 0.7
10.6 1.2
10
Il
9.5 0.8
11.1 1.1
9
9
Stainable aluminum % A
B
48.8 10.0
58.6 11.9
10
11
39.8 11.0
53.1 11.1
9
10
Biochemical aluminum A 1.74 0.39 7 1.19 0.22 7
g/g dry bone B 2.50 0.68 10 1.68 0.47 9
I
4,000
phosphatase, osteocalcin and aluminum values at the start and
at end of the study were not different between groups. Eventual
changes with time of iPTH and osteocalcin in both groups were
studied. Plasma 53-84 iPTH did not change with time in any
group (data not shown); by contrast, plasma 44-68 iPTH in-
creased with time in the control group but not in the acidosis
corrected group (Fig. 2). Plasma osteocalcin increased with
time in both groups (Fig. 3).
Considering the bone histomorphometry data (Table 4), rel-
ative osteoid volume increased in both groups during the study.
Osteoid surfaces and osteoblastic surfaces increased in the
___________________________________________
control group but not in the acidosis corrected group. There
0 3 6 9 12 15 18 were no significant changes between groups or with time in
Time, months bone formation rate, mean osteoid thicknesses, resorption
parameters and biochemical or stainable bone aluminum.
The relationship of two histomorphometric parameters (os-
teoblastic and osteoclastic surfaces) with osteocalcin and IPTH
measured with different antibodies at start and at the end of the
study were studied (Table 5). Resorption and formation param-
eters correlated with all these biochemical values were signifi-
cant. On the second bone biopsy the correlation coefficient of
morphometric parameters with 53-84 PTH was lower than the
one observed with 44-68 PTH, 1-84 FF11 and osteocalcin.
To discover if the effect of acidosis correction was different
according to the type of bone disease, we studied the plasma
osteocalcin levels in the two subgroups, defined on a histomor-
phometric basis at start of the study. In the subgroup of patients
with normal-high bone formation at start of the study, osteo-
calcin increased significantly less with time in the acidosis
phosphate values at the start and at end of the study were
unchanged. Accordingly, predialysis plasma PTH, alkaline
Table 4. Bone histomorphometry at start and at the end of the study
in control (A) and acidosis corrected (B) patients
6,000
Results are expressed by mean 5EM.
a Significantly different at P < 0.05 from the value at start of the studyb Significantly different at P < 0.005 from the value at start of the
0
study
I
2,000
Fig. 2. Evolution with time of 44-68 PTH plasma level in control(O—O) and acidosis corrected (• •) patients. There is a signifi-
cant increase of the values with time in the control group (slope 489.12
230.47, P < 0.05) but not in the acidosis corrected group. Data are
mean SEM.
9 12 15 18
Time, months
30
26
22
18
Fig. 1. Evolution with time of pre- and postdialysis plasma bicarbon-
ate in controls and acidosis corrected patients during the 18 months of
the study. Symbols are: pre- (O—Q) and postdialysis (Ll—E1) values
in control group; pre- (•) and postdialysis (• •) values in
acidosis corrected group. From the third month, values were signifi-
cantly (P < 0.05) higher in acidosis corrected patients than in controls.
Points and bars are mean SEM.
plasma potassium value with time during 18 months of the study
(slope: 0.005 0.002, P < 0.05), whereas in the control group
plasma potassium values did not change during the study.
Table 3 shows that pre- and postdialysis plasma calcium and
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Time, months
Fig. 3. Evolution with time of osteocalcin plasma level in control
(O—O) and acidosis corrected ( •) patients. Values increased
with time in acidosis corrected group (slope 3.29 1.22, P <0.01) and
in the control group (slope 7,30 252, P < 0.005). Data are mean
SEM.
Table 5. Correlation between two histomorphometric parameters
(osteoblastic and resorption surfaces) and plasma osteocalcin or PTH
value measured with different antibodies at start and at the end of the
study
Plasma
Osteoblastic surfaces Resorptio
First
bone
biopsy
n surfaces
Second
bone
biopsy
First
bone
biopsy
Second
bone
biopsy
Osteocalcin
53-84 PTH
44-68 PTH
1.84 PTH
0.69°
0.68'
0.52a
ND
0g4b
0.49a
0.83°
0.870
0.71c
0.72c
0.67'
ND
0.85°
063b
0.86°
0.740
1'
0 3 6 9 12 15 18
Time, months
Fig. 4. A. Evolution with time of plasma osteocalcin levels in the
subgroup of patients with normal-high bone formation. Symbols are:
control (O—O) and acidosis corrected (• •) patients. Results are
expressed by mean SEM. The slope is 12.1 4.04, (P < 0.05) in
control group and 2.27 0.99 (P < 0.03) in acidosis corrected group.
The 2 slopes are different at P < 0.05. B. Evolution with time of plasma
osteocalcin level in the subgroup of patients with normal-low bone
formation. Results are expressed by mean SEM. There is a significant
increase of the values with time in acidosis corrected group (slope 4.63
2.35, P < 0.05) but not in the control group.
month period. This assumption is sustained by an increase,
during the study, of 44-68 iPTH and plasma osteocalcin levels.
In parallel there was an increase with time of osteoformation
A
80
.60
40
'a0
20
1
0 3 6 9 12 15 18
140
100
60
20
50
C
4
30
0
10
B
0 3 6 9 12 15 18
Time, months
a p < 0.05
b P < 0.01
° P < 0.001
corrected than in the control group (Fig, 4A). By contrast in the
subgroup of patients with low bone formation rate plasma
osteocalcin did not change with time in control patients but
increased significantly in acidosis corrected patients (Fig. 4B).
There was no significant change with time in iPTH level when
considering the two subgroups independently.
Finally, the treatment prescribed to the patients during the
three months preceding the start of the study and during the 18
months study was recorded (Table 6). There was no therapeutic
difference between control and acidosis corrected groups ex-
cept for 1 a vitamin D treatment. The prescription of I a vitamin
D, which depended on plasma calcium value, was lower in
acidosis corrected group during the study than during the three
months preceding the study.
Discussion
Our data show that in patients dialyzed with a conventional
amount of bicarbonate in the dialysate, there is a progression of
secondary hyperparathyroidism and bone turnover during an 18
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Table 6. Average drug prescription in the 3 month s preceeding start and during the 18 months of the study
CaCO3 g/day (1 a) Vitamin D p.g/day Aluminum gel giday
Start End Start End Start End
Controls (A)
Acidosis corrected (B)
4.80 2.30 5.0 2.23
3.82 3.38 3.55 2.21
0.40 0.63 0.41 0.61
0.37 0.26 0.14 Ø•77a
3.8 1.7
2.9 1.5
3.0
2.45
1.5
1.4
a Significantly lower at P < 0.05 than the value recorded at start of the study
histomorphometric parameters in this group of patients. The
value of the biochemical parameters we used to evaluate bone
turnover and PTH secretion deserves some comment. The two
different antibodies used to evaluate PTH during the study were
significantly correlated with morphometric parameters of bone
resorption and formation. The relationship between morpho-
metric parameters and 53-84 PTH on the second bone biopsy
was the lower one observed, and this loose correlation might
explain the lack of modification with time of 53-84 PTH during
the study whereas 44-68 PTH and osteocalcin increased during
the same period. In this study 1-84 PTH, measured only at the
time of the second bone biopsy, was not more closely corre-
lated to morphometric parameters than 44-68 PTH; amino
terminal antibodies have been reported to be better predictors
of renal osteodystrophy than other mid-region antibodies [11],
but we could not confirm this findings with the antibodies we
used. Finally osteocalcin, as has already been observed in
dialyzed patients [12, 13], was closely correlated to both
formation and resorption histomorphometric parameters.
All patients had recommended treatment to decrease second-
ary hyperparathyroidism progression: calcium in dialysate was
1.75 mmol/liter; they received oral calcium carbonate and la
vitamin D was prescribed when calcium carbonate was insuffi-
cient to maintain plasma calcium above 9 mg/dl. The partial
inefficacy of such a treatment to prevent progression of second-
ary hyperparathyroidism in some patients has already been
observed [141. In contrast in patients whose acidosis was
optimally corrected by addition of bicarbonate in the dialysate,
44-68 PTH plasma level did not increase during the study.
Therefore, worsening of secondary hyperparathyroidism in the
course of maintenance hemodialysis was prevented by a better
correction of acidosis.
Contrasting with the PTH finding, osteocalcin increased in
both treatment groups. This result can be explained by different
evolution of osteocalcin values according to the subgroup of
patients. The group of dialyzed patients involved in this study
included patients with different levels of bone turnover and
PTH. They were part of a group of patients whose character-
istics related to aluminum overload have already been reported
[101. Only half of the patients had a bone formation rate above
normal value at start of the study. This subgroup of patients had
histological signs of mild to severe secondary hyperparathy-
roidism (HPT) and elevated plasma iPTH. In these patients
plasma osteocalcin increased more in the control group than in
the acidosis corrected group. Therefore, the prevention of
HPT-induced bone turnover progression by acidosis correction
appeared when only patients with secondary hyperparathyroid-
ism were considered.
The effect of acidosis on calcium phosphate metabolism has
been extensively studied in rats in vivo and in vitro. Metabolic
acidosis triggers an increase in bone resorption and a decrease
in bone formation in parathyroidectomized rats [15]. This
finding suggests that the effect of acidosis on bone is indepen-
dent of PTH. Indeed, acidosis enhances in vitro bone resorp-
tion; in organ culture, calcium release from bone is increased by
metabolic acidosis [16] and this effect is mediated through cell
activity [17]. This might be related to the increase in isolated
osteoclast resorption activity observed when the medium pH is
decreased [18]. Clinical study also suggests that acidosis affects
bone independently of PTH. When acidosis is induced by oral
ammonium chloride administration in normal subjects, P1'H is
reported unchanged in most of the studies (19—21). End organ
responsiveness to PTH is not affected since basal nephrogenic
cyclic AMP [20] or calcemic response to PTH injection [221 is
not different from control.
In light of such experimental data we suggest the following
interpretation of our observations: in dialyzed patients acidosis
might contribute to increase bone resorption and therefore
plasma phosphate released from bone; plasma phosphate was
slightly higher in patients whose acidosis was less corrected.
Hypocalcemia, one of the parathormone secretion enhancers, is
partly dependent on hyperphosphatemia during dialysis [1, 2].
The increase in plasma phosphate would induce progression of
secondary hyperparathyroidism and therefore the bone turn-
over rate. Such speculative interpretation cannot be proved,
but is highly suspect when considering the lack of increased
parathyroid secretion [20—22] along with increased bone resorp-
tion [20] observed in normal subjects in whom acidosis was
experimentally created. This interpretation is also in agreement
with the fact that the doses of 1 a(OH)D required to maintain
calcemia above 9 mgldl during the course of the study could be
decreased in patients whose acidosis was better corrected.
Among the patients with normal-low bone remodelling, seven
out of ten had aplastic bone disease. Surprisingly, the evolution
of osteocalcin value in this subgroup was inverse to the one
observed in the subgroup of patients with secondary hyperpara-
thyroidism. Because most of these patients had a pathologically
low bone turnover at start of the study, the increase in osteo-
calcin plasma value could be considered as a positive result.
This subgroup of patients had an important amount of alumi-
num on their bone biopsies. As an average, in the whole group
of patients bone and serum aluminum were not changed accord-
ing to correction of acidosis. Dialysate alkalosis has been
reported to increase aluminum dializability [23], but we did not
observe any change in the aluminum burden after 18 months.
There was no increase in iPTH level to trigger this increase in
osteocalcin. Therefore, we cannot exclude that a correction of
acidosis per se stimulated the low bone turnover of these
patients. Indeed, in acidotic rats bone formation rate was
markedly decreased [15].
In conclusion, an optimal correction of acidosis has a bene-
ficial effect on dialyzed patient's renal osteodystrophy. We
showed that it could prevent progression of secondary hyper-
1118 Lefebvre et a!: Dialysis osteodystrophy
parathyroidism. Furthermore, it might increase bone formation
in the subgroup of dialyzed patients with low bone turnover.
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